Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression
Year: 2024
Type: article
Study design: Observational Study
Abstract: Aim: The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer.Patients & methods: Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known BRCA mutation, interval debulking surgery or no surgery, or visible residual disease.Results: Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS.Conclusion: Risk profiles should be carefully considered when planning clinical care.
Source: Future Oncology
Institutions: Imperial College London, Clatterbridge Cancer Centre NHS Foundation Trust, Royal Cornwall Hospital Trust, Royal Cornwall Hospital, Universitätsklinikum Tübingen, Hospital Universitario Miguel Servet, Queen Alexandra Hospital, Hospital Universitari Sant Joan de Reus, Fondazione IRCCS Istituto Nazionale dei Tumori, GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), GlaxoSmithKline (Italy), University Hospital Münster, University Hospital Schleswig-Holstein
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: GlaxoSmithKline
OpenAlex ID: W4403734236